The oncogenic roles of p53 mutants in mouse models
- 28 February 2007
- journal article
- review article
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 17 (1), 66-70
- https://doi.org/10.1016/j.gde.2006.12.003
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53Oncogene, 2005
- Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of FunctionCancer Research, 2004
- Introduction: p53 Regulation—A Family AffairCell Cycle, 2004
- Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosisThe EMBO Journal, 2001
- Post‐translational modifications and activation of p53 by genotoxic stressesEuropean Journal of Biochemistry, 2001
- p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative ActivitiesMolecular Cell, 1998
- p53: puzzle and paradigm.Genes & Development, 1996
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Gain of function mutations in p53Nature Genetics, 1993
- The p53 tumour suppressor geneNature, 1991